
SKLB1002
CAS No. 1225451-84-2
SKLB1002 ( SKLB1002 | SKLB 1002 | SKLB1002 )
产品货号. M17891 CAS No. 1225451-84-2
SKLB1002 是一种有效的 ATP 竞争性 VEGFR2 抑制剂,IC50 为 32 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥405 | 有现货 |
![]() ![]() |
5MG | ¥575 | 有现货 |
![]() ![]() |
10MG | ¥770 | 有现货 |
![]() ![]() |
25MG | ¥1750 | 有现货 |
![]() ![]() |
50MG | ¥2916 | 有现货 |
![]() ![]() |
100MG | ¥4739 | 有现货 |
![]() ![]() |
500MG | ¥10287 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称SKLB1002
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SKLB1002 是一种有效的 ATP 竞争性 VEGFR2 抑制剂,IC50 为 32 nM。
-
产品描述SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation. Western blot analysis was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src. In vivo zebrafish model experiments showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos. SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.
-
体外实验——
-
体内实验——
-
同义词SKLB1002 | SKLB 1002 | SKLB1002
-
通路Others
-
靶点Other Targets
-
受体VEGFR2
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1225451-84-2
-
分子量320.39
-
分子式C13H12N4O2S2
-
纯度>98% (HPLC)
-
溶解度DMSO : 5.625 mg/mL 17.56 mM;
-
SMILESCOc1c(OC)cc2c(Sc3nnc(C)s3)ncnc2c1
-
化学全称2-((6,7-dimethoxyquinazolin-4-yl)thio)-5-methyl-1,3,4-thiadiazole
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zhang S, et al. Clin Y Res. 2011, 17(13), 4439-4450.
产品手册




关联产品
-
Dansylamide
丹磺酰酰胺是一种荧光染料,用于生物化学和化学,用荧光丹磺酰基团标记物质。
-
1,3-Diphenylisobenzo...
1,3-二苯基异苯并呋喃是一种荧光探针。它对单线态氧具有高度特异性的反应活性,形成内过氧化物,内过氧化物分解生成 1,2-二苯甲酰苯。 1,3-二苯基异苯并呋喃可以检测活性氧(ROS)的产生。
-
6-Hydroxykaempferol ...
6-Hydroxykaempferol 3,6-di-O-glucoside and 6-hydroxykaempferol 3,6,7-tri-O-glucoside can inhibit platelet aggregation induced by collagen, they also show weak inhibitory effects on the adenosine 5'-diphosphate (ADP)- induced platelet aggregation.